Larimar Therapeutics (NASDAQ:LRMR) shows heightened trading activity, advancing rare disease therapies with CTI-1601 through structured Phase 2 trials, supported by robust research, clinical programs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback